Results 181 to 190 of about 207,511 (311)

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia   +18 more
wiley   +1 more source

Improved Detection of Myositis‐Specific Autoantibodies Using Luciferase Immunoprecipitation Systems Assay: Comparison with Line Blot and Conventional Immunoprecipitation

open access: yesArthritis &Rheumatology, Accepted Article.
Background Myositis‐specific autoantibodies guide the diagnosis and classification of idiopathic inflammatory myopathies, but current immunoassays vary in accuracy, particularly for autoantibodies associated with interstitial lung disease. Objective To compare the performance of the luciferase immunoprecipitation systems (LIPS) assay with line blot and
Peter D. Burbelo   +14 more
wiley   +1 more source

Nintedanib for progressive pulmonary fibrosis in real-world setting: an observational study comparing outcomes with an IPF cohort. [PDF]

open access: yesBMC Pulm Med
Muscato G   +9 more
europepmc   +1 more source

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long‐term multicenter observational study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Osteoporosis causes fractures which further increase the disease burden of rheumatoid arthritis (RA), however, osteoporosis treatment rates remain low. While several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi   +30 more
wiley   +1 more source

Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma. [PDF]

open access: yesFront Med (Lausanne)
Zanini U   +8 more
europepmc   +1 more source

Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel   +4 more
wiley   +1 more source

Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy

open access: yesBMEMat, EarlyView.
Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim   +5 more
wiley   +1 more source

Toxic interstitial lung disease in cattle. [PDF]

open access: yesJ Vet Diagn Invest
Barros CSL   +3 more
europepmc   +1 more source

Nano‐networks via reaction‐induced self‐assembly coordinate spatiotemporal multi‐drug delivery for acute kidney injury therapy

open access: yesBMEMat, EarlyView.
Multifunctional nano‐networks (NNWs) are prepared via reaction‐induced self‐assembly (RISA) of spermidine (SPD), epigallocatechin gallate (EGCG), 2‐formylphenylboronic acid (2‐FPBA), and deferoxamine (DFO) through dynamic iminoboronate bonds. These NNWs leverage the oxidative AKI microenvironment to trigger disintegration, enabling site‐specific ...
Juan Jin   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy